

Original Article

Healthcare associated infections caused by non-fermenting Gram negative rods (NFGNR): six years of experience of a tertiary hospital

Zahidul Hasan¹, Md. Kamrul Islam², Arifa Hossain¹

¹Microbiology Department, Square Hospitals Ltd, Infection Control, Clinical Governance and Systems, ICDDRB.

²Infection Control Program, Square Hospitals Ltd.

Abstract

Recently non-fermenting Gram negative rods (NFGNR) are playing an important role in healthcare associated infections. This observational study in a tertiary care hospital of Dhaka city conducted during 01 August 2007 to 30 June 2013 found that 34.8% isolated organisms from patients with healthcare associated infections were NFGNR. Majority (74.3 %) of these infections were occurring inside critical care areas. *Pseudomonas* and *Acinetobacter* together constituted 79.6% of the total NFGNR whereas *Burkholderia cephalica* complex (15.4%), *Stenotrophomonas* (4.3%) and *Chryseobacterium* species (0.7%) combined constituted remaining 20.4%. Out of total NFGNRs, *Pseudomonas* was responsible for highest number of catheter associated urinary tract infections (55.6%), ventilator associated pneumonia (46.3%), respiratory tract infection (65.8%) and surgical site infection (70.6%). Blood stream infection was predominantly caused by *Burkholderia cephalica* complex (33.5%) and *Acinetobacter* spp. (39.5%). Other than colistin most of the organisms were resistant to antibiotics commonly recommended for NFGNR.

Key words: NFGNR, HAI.

Introduction:

Non-fermenting Gram negative rods (NFGNR) are a diverse group of opportunistic pathogens that either do not utilize carbohydrate as a source of energy or utilize it in oxidative pathway¹. It is difficult to manage patients infected by NFGNR because of failure to identify some of the members of this group in the laboratory and lack of options of treatment as most of them are resistant to common antibiotics¹⁻³. Most members of this group remain in hospital environment as saprophyte and some in human gut as normal flora⁴⁻⁵. Previously many of them were considered as non virulent organisms. In recent time NFGNR have emerged as opportunist specially for immunosuppressed patients causing healthcare-associated infections (HAI) such as septicemia, meningitis, pneumonia, urinary tract infections (UTI), and surgical site infections (SSI)^{4,6}.

Important members of the group include *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, *Stenotrophomonas maltophilia*, and *Burkholderia cephalica*^{3,7}. Most of them are frequently found resistant to common antibiotics including antipseudomonal penicillins and cephalosporins, aminoglycosides, tetracyclines, fluoroquinolones, trimethoprim-sulfamethoxazole, and carbapenems. However, polymyxins shows fairly consistent activity against multidrug-resistant strains of *Pseudomonas*, *Acinetobacter* and *Stenotrophomonas* species³.

Among the NFGNR *Pseudomonas* is the most commonly isolated organism followed by *Acinetobacter*. Both are ubiquitous in nature and found in water and moist environment^{2,8}. However, *Acinetobacter* is oxidase negative bacteria commonly found inside ventilators, humidifiers and catheters. The organism is increasingly responsible for outbreaks of infections among hospitalized patients, particularly in intensive care units. Antibiotic resistance has become a common phenomenon⁹⁻¹¹. There are alarming reports of infections caused by carbapenem-resistant *Acinetobacter* spp¹²⁻¹⁵.

✉ Correspondence:

Professor Zahidul Hasan
Consultant- Microbiology, Square Hospitals Ltd
18/F Bir Uttam Qazi Nuruzzaman Sarak
(West Panthapath), Dhaka 1205
E- mail: Zahidul@squarehospital.com
Telephone: (880-2) 8159457-64 (PABX), Ext-6121

Burkholderia cephalica complex (BCC), comprised of a group of some closely related bacterial species is another common non-fermentor that cause HAI and infections to patients suffering from cystic fibrosis¹⁶. As per recommendation by Clinical and Laboratory Standards Institute (CLSI) their susceptibility is limited to ceftazidime, meropenem, minocycline and cotrimoxazole only¹⁷. *Stenotrophomonas maltophilia* is another organism in this group though it is not considered as normal flora of human body. The organism is inherently resistant to anti-pseudomonal drugs and sensitive to co-trimoxazole. For detection of antibiotic susceptibility CLSI recommends broth dilution test, but if disc diffusion test is to be performed it should be done only against minocycline, levofloxacin and co-trimoxazole. Antimicrobial sensitivity of *Chryseobacterium*, another bacteria of hospital environment causing neonatal infections with high mortality rate, should be determined by dilution method as disc diffusion method does not give reliable results.

In Bangladesh there is hardly any comprehensive report on healthcare associated infections caused by these organisms. Lack of laboratory facilities to correctly identify some members of this group is an important factor for under reporting of these organisms. This study was undertaken to observe the role of NFGNR in causing healthcare associated infections in a tertiary care hospital of Dhaka city.

Materials And Methods:

This observational study on non-fermenting Gram negative rods was carried out in a tertiary care corporate hospital of Dhaka city. As a part of infection control program the hospital has got an ongoing active surveillance for detection of healthcare associated infections. For this study data were collected from 01 August 2007 to 30 June 2013 during which a total of 87608 patients were admitted in the hospital. Among them 1451 patients suffered from healthcare associated infections. Total number of non-fermenting Gram negative rods isolated from HAI cases during this period was 602 which constituted the study population. Determination of HAI was carried out by the surveillance protocol formulated by the hospital authority as follows. Every morning, temperature chart along with patient's identification (ID) number, collected from nurse stations, was sent to infection control (IC) team (who have received training on data collection). The team then entered the ID number of febrile patients (temperature >100°C) into the computer to retrieve patient's relevant information regarding infection. This included culture sensitivity test, complete blood count (CBC), use of clinical devices such as urinary catheter, respiratory equipments, central venous line etc, chest X-ray report and

other pathological test reports indicating infection that occurred at least 48 hours after hospital admission. Suspected patients were visited by the IC team before including them as a case of HAI. If there was any confusion whether the patient was eligible to be included as HAI, treating physician was consulted. Isolation of organism/s from the appropriate sample of a febrile patient relevant with appropriate clinical features and/or positive pathological tests indicating infection was the criteria for inclusion as study subject.

Most of the common bacteria were identified by standard manual methods practiced in the hospital laboratory¹⁸. However, identification of non-fermenting Gram negative rods (NFGNR) which included *Pseudomonas*, *Acinetobacter*, *Burkholderia*, *Stenotrophomonas* and *Chryseobacterium* needed few more other tests^{5,19}. The organisms that gave doubtful results were identified by automated identification system (Phoenix BD). Automated identification system was only used for those bacteria that gave confusing results and posed problems for identification. Antibiotic sensitivity was determined by disc diffusion method²⁰. Selection of antibiotics for each group of bacteria were made as per recommendation made by Clinical and Laboratory Standards Institute (CLSI) 2010, guideline¹⁷. *Pseudomonas aeruginosa* ATCC 27853 was used as control strain. Antibiotics used for sensitivity test by disc diffusion method were amikacin, aztreonam, cefepime, ceftazidime, ciprofloxacin, gentamycin, meropenem, co-trimoxazole, piperacillin, piperacillin + tazobactam and colistin.

Data collection was done by members of infection control team who filled up the HAI surveillance form for each patient. Data were analyzed by entering the data in SPSS version¹².

Results:

During August 2007 to June 2013, a total of 87608 patients were admitted, of which 1451 had healthcare associated infections (HAI) with an infection rate of 1.6 %. From these patients 1726 organisms were isolated, of which 602 (34.8%) were non-fermenting Gram negative rods that included *Pseudomonas*, *Acinetobacter*, *Burkholderia*, *Stenotrophomonas* and *Chryseobacterium* species. Though age of the subjects ranged between 5 days to 103 years the mean and median were 51.2 and 57 years respectively. The age of 43% of total HAI affected patients were 60 plus and males predominated over females (62% vs. 38%).

Table 1 showed the distribution of 602 non-fermenting Gram negative rods (NFGNR). *Pseudomonas* and *Acinetobacter*

species together constituted more than three quarter (79.6%) of the total NFGNR whereas Burkholderia (15.4%), Stenotrophomonas (4.3%) and Chryseobacterium species (0.7%) together constituted less than a quarter (20.4%).

Table 2 showed that out of total NFGNR induced infections most of the urinary tract infections (UTI; 83.3%) were caused by Pseudomonas. Similarly Pseudomonas was responsible for highest number of catheter associated urinary tract infections (CAUTI; 55.6%), ventilator associated pneumonia (VAP; 46.3%), respiratory tract infection (RTI; 65.8%) and surgical site infection (SSI; 70.6%). However blood stream infections were predominantly caused by Burkholderia cephalica complex (BCC; 39.5%) and Acinetobacter species (33.5%). Only 4 Chryseobacterium species were isolated and all were found in blood stream infection.

Most (74.3%) of the organisms were isolated from the patients at critical care areas and remaining 25.7% were isolated from the patients admitted in non critical areas such as cabins and high density units (wards) (table 3). Critical care areas included general Intensive Care Unit (ICU), Neonatal ICU (NICU), Pediatric ICU (PICU), Cardiothoracic ICU (CTICU), Neuro-ICU and Coronary Care Unit (CCU) (table 3). Major contributor was the general ICU where more than half (307; 51%) of the NFGNRs were isolated. Pseudomonas predominated in ICU, PICU and non-critical areas whereas Acinetobacter predominated in NICU, CTICU and Neuro ICU.

Table 4 showed antimicrobial sensitivity of isolated NFGNRs. Among the Pseudomonas species highest (56.9%) sensitivity was recorded against the combination of piperacillin-tazobactam. This was followed by piperacillin (44.5%) and meropenem (40.6%). Almost two third of the Pseudomonas were resistant to remaining drugs. Only 23.9% and 20.1% of isolated Acinetobacter specimen were sensitive to meropenem and amikacin respectively. Sensitivity to other antibiotics was even lesser ranging between 4.1 to 18.7%. However, Burkholderia showed good sensitivity to ceftazidime (85.7%), meropenem (85.7%), piperacillin-tazobactam (84.2%) and cotrimoxazole (78%). only 57% of stenotrophomonas were found sensitive to cotrimoxazole and 50% to ciprofloxacin. Though disc diffusion method is not recommended for Chryseobacterium, sensitivity to piperacillin-tazobactam and meropenem were found to be 33.3% and 25% respectively. Colistin was found sensitive to all of the isolated Pseudomonas, Acinetobacter, Stenotrophomonas and Chryseobacterium species. Burkholderia cephalica complex were resistant to colistin.

Table-1: Distributions of isolated non-fermenting gram negative rods (NFGNR)

NFGNR	No	%
<i>Pseudomonas spp.</i>	266	44.2
<i>Acinetobacter spp.</i>	213	35.4
Burkholderia cephalica complex	93	15.4
<i>Stenotrophomonas spp.</i>	26	4.3
<i>Chryseobacterium spp.</i>	4	0.7
Total	602	100

Table 2: Healthcare associated infections caused by NFGNR

NFGNR	UTI	CAUTI	VAP	RTI	BSI	SSI	Other	Total
Pse	10 (83.3)	30 (55.6)	124 (46.3)	25 (65.8)	36 (21.6)	36 (70.6)	5 (41.7)	266
Aci	1 (8.3)	21 (38.8)	107 (39.9)	10 (26.3)	56 (33.5)	13 (25.5)	5 (41.7)	213
Bur	0 (00)	2 (3.7)	20 (7.5)	2 (5.3)	66 (39.5)	2 (3.9)	1 (8.3)	93
Ste	1 (8.3)	1 (1.9)	17 (6.3)	1 (2.6)	5 (3.0)	0 (00)	1 (8.3)	26
Chr	0 (00)	0 (00)	0 (00)	0 (00)	4 (2.4)	0 (00)	0 (00)	4
Total	12 (100)	54 (100)	268 (100)	38 (100)	167 (100)	51 (100)	12 (100)	602

Note: 1. Pse= Pseudomonas; Aci= Acinetobacter; Bur= Burkholderia; Ste= Stenotrophomonas; Chr= Chryseobacterium; UTI= urinary tract infection; CAUTI= catheter associated urinarytract infection; VAP= ventilator associated pneumonia; RTI= respiratory tract infection (other than VAP); BSI= blood stream infection; SSI= surgical site infection. Note 2: Figure in the parenthesis is the percentage among each type of HAI

Table-3: NFGNR causing healthcare associated infections in critical and noncritical areas

NFGNB	Non-critical area	ICU	NICU	PICU	CTICU	CCU	Neuro ICU	Total
Ps	75 (48.4)	147 (47.9)	17 (26.6)	3 (30)	6 (27.3)	5 (50)	13 (38.2)	266
Aci	44 (28.4)	108 (35.2)	34 (53.1)	2 (20)	8 (36.4)	1 (10)	16 (47.1)	213
Bur	33 (21.3)	40 (13.0)	7 (10.9)	2 (20)	6 (27.3)	3 (30)	2 (5.9)	93
Sten	3 (1.9)	12 (3.9)	2 (3.1)	3 (30)	2 (9.0)	1 (10)	3 (8.8)	26
Chry	0 (00)	0 (00)	4 (6.3)	0 (00)	0 (00)	0 (00)	0 (00)	4
Total	155	307	64	10	22	10	34	602

Note: 1. Figures in parenthesis indicates percentage among each area; 2. Critical care areas include Intensive care unit (ICU), Neonatal ICU (NICU), Paediatric ICU (PICU), Cardiothoracic ICU (CTICU), Coronary care unit (CCU) and Neuro-ICU

Table-4: Antimicrobial sensitivity pattern of isolated NFGNB (showing susceptible percentage)

Antibiotics	Pseudomonas N= 266	Acinetobacter N= 213	Burkholderia N= 93	Stenotrophomonas N= 26	Chryseobacterium N= 4
Amikacin	34.5	20.1	6.7	00	00
Aztreonam	39.6	4.1	60	00	00
Cefepime	35.3	15.7	30.7	22.2	00
Ceftazidime	35	13.7	85.7	21.4	00
Ciprofloxacin	34.3	16.5	53	50	50
Gentamycin	30.8	17.4	4	14	00
Meropenem	40.6	23.9	85.7	00	25
Piperacillin	44.5	8.9	75	40	00
Piperacillin + tazobactam	56.9	16.9	84.2	44.4	33.3
Cotrimoxazole	-	18.7	78	57	-
Colistin	100	100	00	100	100

Discussion:

Recently there is a worldwide upsurge of healthcare associated infections caused by NFGNR. Management of infections caused by these organisms is difficult for two distinct reasons. First, it is difficult to identify them as most of the laboratories are not yet fully organized to do so. To some extent this is a universal problem as many of these organisms were previously classed under *Pseudomonas* or other genera and until recently they were considered as bacteria of lesser importance because of their relatively less virulent nature^{21,22}. And the second difficulty is that, many of them are inherently resistant to common antibiotics³⁻⁵.

Literatures reveal that among NFGNRs, *Pseudomonas* and *Acinetobacter* species play major role in causation of HAI, worldwide⁸. This study showed similar trend, as *Pseudomonas* and *Acinetobacter* together constituted almost eighty percent of our study population. This scenario is specially pronounced in intensive care units⁸. One of the important reasons for their dominance is that they have the ability to thrive in moist environment and have the capacity to survive in dry and inanimate surface even for up to six months²³⁻²⁵. *Pseudomonas* species is also inherently resistant to many antimicrobial agents. Susceptible strains are usually treated by piperacillin, ticarcillin, ceftazidime, cefepime, carbapenems, aminoglycosides or fluoroquinolones alone or in combinations. Recently there is alarming rise of multi drug resistant strains along with a few reports of pan resistance²⁶. Our study also revealed a disheartening scenario. Other than colistin no antibiotic could confidently be singled out for empirical treatment. Only piperacillin-tazobactam combination showed sensitivity against more than half (57%) of isolated *Pseudomonas*. Sensitivity to other antipseudomonal antibiotics was poor (ranging between 30-44%). Enzyme production, over expression of efflux pumps, porin deficiencies, and target-site alterations could be the major mechanisms for drug resistance among *Pseudomonas* and other Gram-negative nonfermenters⁶.

Acinetobacter is another organism responsible for various healthcare associated infections including bacteremia, pneumonia, meningitis, urinary tract infection, and wound infection^{27,28}. Drug resistance is very common and treatment option has become severely depleted. For treatment of drug resistant *Acinetobacter*, carbapenem and colistin are the agents of choice though strains resistant to all antimicrobial agents, including colistin have been reported²⁸. This has created a serious threat for treatment of healthcare associated infections²⁹. In our study we found that all were sensitive to colistin though only 23.9% were sensitive to carbapenem.

Burkholderia cephalica complex (BCC) one of the common pathogenic NFGNBs worldwide after *Pseudomonas*, *Acinetobacter* and *Stenotrophomonas* species has emerged as an important cause of morbidity and mortality in hospitalized patients largely because of high intrinsic antibiotic resistance¹⁶. BCC is responsible for many cases of septicemia and pneumonia in intensive care, oncology and hemodialysis units. In addition it can cause infection of skin and genitourinary tract as well^{30,31}. In this study we found that 96% of isolated BCC were involved in bloodstream and respiratory tract infection with negligible infections at other sites.

A common mistake made by many laboratories is that BCC is reported as *Pseudomonas*. BCC is intrinsically resistant to anti-Pseudomonal agents like aminoglycosides, antipseudomonal penicillins and polymyxins which are commonly used against *Pseudomonas* infections. In such situations treatment failure is inevitable when aforementioned antibiotics are given to a BCC infected patient because of misdiagnosis by the laboratory. This highlights the importance of proper identification of NFGNR¹⁶.

Chryseobacterium meningosepticum is an organism associated with meningitis in premature neonates³². They are found primarily in soil and water and even can survive in chlorine-treated water supplies. Colonization of patients through respirators, intubation tubes, humidifiers, incubators and syringes has been documented^{33,34}. As an opportunistic pathogen they infect mainly newborns and immunocompromised hosts of all age groups causing meningitis, bacteremia, pneumonia, endocarditis, infections of skin, soft tissue, ocular and other infections^{35,36}. They are mostly resistant to aminoglycosides, tetracyclines, chloramphenicol, erythromycin, clindamycin, and teicoplanin. However, fluoroquinolones, minocycline, doxycycline, trimethoprim-sulfamethoxazole and rifampin can be used depending on susceptibility³⁵. In this study total number of isolated *Chryseobacterium* were only 4 which preclude us to make any useful comment on antibiotic sensitivity. Moreover, we used disc diffusion method for detection of antimicrobial sensitivity which is not the recommended for *Chryseobacterium*.

Stenotrophomonas maltophilia was previously known as *Pseudomonas maltophilia* and also as *Xanthomonas maltophilia*. *Maltophilia* is the only species under this genus. *S. maltophilia* is associated with bacteremia, endocarditis, respiratory, urinary tract, CNS soft tissue, bone marrow and ocular infections. Infections caused by *S. maltophilia* are particularly difficult to manage because they are frequently

resistant to many antimicrobial agents^{37,38}. Though co-trimoxazole is the main therapeutic option, limited data suggest that ciprofloxacin, ceftazidime or ceftriaxone, and ticarcillin/clavulanate, alone or in combination with other antibiotics, may be considered as alternative options³⁹. In our study only 57% of isolated *Stenotrophomonas* were sensitive to co-trimoxazole. Colistin is the only antibiotic with 100% susceptibility against isolated *Pseudomonas*, *Acinetobacter*, *Stenotrophomonas* and *Chryseobacterium*. *Burkholderia cepacia* is inherently resistant to colistin. But, problem with colistin is that it carries the risk of nephrotoxicity particularly among elders³.

Literatures suggest that worldwide HAI caused by non-fermenting Gram negative rods are on rise. Our study also reveal similar scenario and it is a matter of concern that almost one out of three organisms causing HAI is NFGNR which are showing an alarming rate of antimicrobial resistance. We have hardly any data on antibiotic sensitivity pattern of NFGNR originated from the community. It is expected that resident organisms of hospital specially of ICU are relatively more resistant to antibiotics than those coming from community. Our hospital's annual antibiogram also shows that organisms of indoor patients are more resistant to antibiotics than that of outdoor patients which corroborates with findings of other literatures. This study is reflecting the situation prevailing in a tertiary care hospital of Dhaka city and it can be guessed that situation of other hospitals are not far different.

Unfortunately, with exception of a few, most of our laboratories are not yet organized enough to identify various NFGNR with confidence. Consequently, due to poor laboratory support the physicians are facing difficulties in treating infections caused by these organisms. Patients are unnecessarily being exposed to expensive antibiotics and prolonged hospital stay with increased morbidity and mortality. Lack of facilities as well as lack of awareness among the healthcare personnel is partly responsible for this situation. Identification of the NFGNR with appropriate sensitivity testing will play an important role in minimizing morbidity and mortality of patients suffering from healthcare associated infections.

Reference:

1. Winn W Jr, Allen S, Janda W, Koneman E, Procop G, Schreckenberger P, editors. In: Koneman's Color Atlas and textbook of Diagnostic Microbiology. 6th ed. USA: Lippincott Williams and Wilkins Company; 2006. Nonfermenting Gram negative bacilli; pp. 305-91.
2. Su SC, Vanechoutte M, Dijkshoorn L, Wei YF, Chen Y L and Chang TC. Identification of non-fermenting Gram-negative bacteria of clinical importance by an oligonucleotide array. *Journal of Medical Microbiology*. 2009; 58: 596-605.
3. McGowan JE Jr. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. *Am J Infect Control*. 2006 Jun; 34(5 Suppl 1):S29-37.
4. Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant *Acinetobacter* species and *Stenotrophomonas maltophilia* as pathogens in seriously ill patients: Geographic patterns, Epidemiological features, and trends in the SENTRY antimicrobial surveillance program (1997-1999) *Clin Infect Dis*. 2001; 32:104-13.
5. Malini A, Deepa EK, Gokul BN and Prasad SR. Nonfermenting Gram-Negative Bacilli Infections in a Tertiary Care Hospital in Kolar, Karnataka. *J Lab Physicians*. 2009 Jul-Dec; 1(2): 62-6.
6. Enoch DA, Birkett CI, Ludlam HA. Non-fermentative Gram negative bacteria. *Int J Antimicrobial Agents* 2007 May; 29 Suppl. 3:533- 41.
7. Connie R Mahon, Donald C. Lehman and George Manuselis editors. Text book of Diagnostic Microbiology. Fourth edition. Sanders, ELSEVIER, 2011 P. 564-577
8. Nahar A, Anwar S, Saleh AA and Miah MRA. Isolation of *Acinetobacter* species and their antimicrobial resistance pattern in an intensive care unit (ICU) of a tertiary care hospital in Dhaka, Bangladesh. *Bangladesh J Med Microbiol*; 06 (01): 3-6.
9. Allen DM, Hartman BJ. *Acinetobacter* species. In: Mandell G L, Bennett J E, Dolin R, editors. Principles and Practice of Infectious Diseases. 5th ed. Philadelphia: Churchill Livingstone; 2000. P. 2339-42.
10. Villegas MV, Hartstein AI. *Acinetobacter* outbreaks, 1977-2000. *Infect Control Hosp Epidemiol* 2003; 24:284-95.
11. Niederman MS. Impact of antibiotic resistance on clinical outcomes and the cost of care. *Crit Care Med* 2001; 29:N114-N120
12. Bou G, Cervero G, Dominguez MA, Quereda C, Martinez-Beltran J. Characterization of a nosocomial outbreak caused by a multiresistant *Acinetobacter baumannii* strain with a carbapenem-hydrolyzing enzyme: High-level carbapenem resistance in A.

- baumannii is not due solely to the presence of beta-lactamases. *J Clin Microbiol* 2000; 38:3299-305
13. Corbella X, Montero A, Pujol M, Dominguez MA, Ayats J, Argerich MJ et al. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant *Acinetobacter baumannii*. *J Clin Microbiol* 2000; 38: 4086-95.
 14. Quale J, Bratu S, Landman D, Heddurshetti R. Molecular epidemiology and mechanisms of Carbapenem resistance in *Acinetobacter baumannii* endemic in New York City. *Clin Infect Dis* 2003; 37:214-20
 15. Fournier PE and Ritchen H. The epidemiology and control of *Acinetobacter baumannii* in health care facilities. *Clin Infect Dis* 2006 Mar 1; 42(5):692-9.
 16. LiPuma JJ CB, Lum GD, Vandamme PAR. Burkholderia, Stenotrophomonas, Ralstonia, Cupriavidus, Pandoraea, Brevundimonas, Comamonas and Acidovorax. In: Murray PR BE, Jorgensen JH, Landry ML, Pfaller MA, editors. *Manual of clinical Microbiology*. Washington, DC: ASM Press; 2007. P. 749-69.
 17. Performance Standards for Antimicrobial Susceptibility Testinf; Twentieth Informational Supplement 2010. M100-s20, Vol (30):1, Clinical And Laboratory Standards Institute, Wayne, Pennsylvania, USA.
 18. Forbes BA, Sham DF, Weissfeld AS. Baily and Scott's Diagnostic Microbiology, 11th Edition, Mosby, 2002P. 378-98.
 19. Rubin SJ, Granato PA, Wasilauskas BL. Glucose nonfermenting Gram negative bacteria. In: Lennette EH, Balows A, Hausler WJ Jr, Shadomy HJ, editors. *Manual of Clinical Microbiology*. 4th ed. Washington, D.C: American Society for Microbiology; 1985. P. 330-49.
 20. Bauer AW, Kirby WMM, Sherris JC and Turec M. Antibiotic susceptibility testing by a standardized single disk method. *Am J Clin Pathol* 1966; 45(4): 493-6.
 21. Laffineur K, Janssens M, Charlier J, Avesani V, Wauters G and Delmée M. Biochemical and Susceptibility Tests Useful for Identification of Nonfermenting Gram-Negative Rods. *J. Clin. Microbiol.* 2002, 40(3):1085-7
 22. Gautam V, Singhal L, Ray P. Burkholderia cepacia complex: Beyond Pseudomonas and Acinetobacter. *Indian J Med Microbiol* 2011; 29:4-12
 23. Hall J, Hodgson G, Kerr KG. Provision of safe potable water for immunocompromised patients in hospital. *J Hosp Infect.* 2004; 58:155-8.
 24. Trautmann M, Halder S, et al. Point-of-use filtration reduces endemic *Pseudomonas aeruginosa* infections on a surgical intensive care unit. *Am J Infect Control.* 2008;36:421-9.
 25. Stojek NM, Szymanska J, Dutkiewicz J. Gram-negative bacteria in water distribution systems of hospitals. *Ann Agric Environ Med.* 2008;15:135-142.
 26. Hsueh PR, Tseng SP Teng LI and HoSW. Pan-drug-resistant *Pseudomonas aeruginosa* causing nosocomial infection at a university hospital in Taiwan. *Clin Microbiol Infect.* 2005 Aug; 11(8): 670-3.
 27. Maragakis LL and Perl TM. *Acinetobacter baumannii*: epidemiology, antimicrobial resistance, and treatment options. *Clin Infect Dis.* 2008 Apr 15; 46(8):1254-63.
 28. Manchanda V, Sanchaita S, Singh NP Multidrug Resistant *Acinetobacter*. *J Glob Infect Dis.* 2010 Sep-Dec; 2(3): 291-304.
 29. Gales AC, Jones RN and Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54731 clinical isolates of gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). *Clin Microbiol Infect* 2006; 12:315-21.
 30. Dizbay M, Tunccan OG, Sezer BE, Aktas F, Arman D. Nosocomial Burkholderia cepacia infections in a Turkish university hospital: a five-year surveillance. *J Infect Dev Ctries* 2009; 3(4):273-7.
 31. Abe K, D'Angelo MT, Sunenshine R, Noble-Wang J, Cope J, Jensen B, et al. Outbreak of Burkholderia cepacia bloodstream infection at an outpatient hematology and oncology practice. *Infect Control Hosp Epidemiol* 2007; 28:1311-3.
 32. Mohammad I. Issack and Neetoo Y. An outbreak of Elizabethkingia meningoseptica neonatal meningitis in Mauritius. *J Infect Dev Ctries* 2011; 5(12):834-9.
 33. Du Moulin GC. 1979. Airway colonization by Flavobacterium in an intensive care unit. *J. Clin. Microbiol.* 10:155-60.
 34. Hoque SN, Graham J, Kaufmann M E, and Tabaqchali S. Chryseobacterium (Flavobacterium) meningosepticum outbreak associated with colonization of water taps in a neonatal intensive care unit. *J. Hosp. Infect.* 2001; 47:188-92.
 35. Bloch KC, Nadarajah R and Jacobs R. Chryseobacterium

- meningosepticum: an emerging pathogen among immunocompromised adults. Report of 6 cases and literature review. *Medicine* 1997 Jan; 76(1): 30-41.
36. Kirby JT, Sader HS, Walsh TR, and Jones RN. Antimicrobial Susceptibility and Epidemiology of a Worldwide Collection of *Chryseobacterium* spp.: Report from the SENTRY. Antimicrobial Surveillance Program (1997-2001). *Journal of Clinical Microbiology*, Jan. 2004, p. 445-448.
37. Denton M and Kerr KG. Microbiological and Clinical Aspects of Infection Associated with *Stenotrophomonas maltophilia*. *Clinical Microbiology Reviews*. Jan. 1998, p. 57-80
38. Muder RR, Yu VL, Dummer JS et al. Infections caused by *Pseudomonas maltophilia*: expanding clinical spectrum. *Arch Intern Med* 1987; 147: 1672-4.
39. Falagas ME, Valkimadi PE, Huang YT, Matthaiou DK and Hsueh PR. Therapeutic options for *Stenotrophomonas maltophilia* infections beyond cotrimoxazole: a systematic review. *Journal of Antimicrobial Chemotherapy* 2008; 62, 889-894.